Sulfated hexasaccharides attenuate metastasis by inhibition of p-selectin and heparanase

Neoplasia

Volumn 13, Issue 5, 2011, Pages 445-452

  Borsig, Lubor ^a   Vlodavsky, Israel ^b   Ishai Michaeli, Rivka ^c   Torri, Giangiacomo ^d   Vismara, Elena ^e  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d Istituto di Ricerche Chimiche e Biochimiche G Ronzoni   (Italy)

^e POLITECNICO DI MILANO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ENDOGLYCOSIDASE; GLYCOSIDASE; HEPARANASE; PADGEM PROTEIN; SELECTIN; SULFATED TRI MANNOSE C C LINKED DIMER; SULFATED TRI MANNOSE C C LINKED DIMER ALPHA ALPHA; SULFATED TRI MANNOSE C C LINKED DIMER ALPHA BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL INTERACTION; CHEMICAL BOND; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; IN VIVO STUDY; METASTASIS; MOLECULAR SIZE; MOLECULAR STABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; VASCULAR ENDOTHELIUM;

EID: 79955789067     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.101734     Document Type: Article

References (66)

1. Nguyen DX, Bos PD, and Massague J (2009). Metastasis: from dissemination toorgan-specific colonization. Nat Rev Cancer 9, 274-284.
2. Barash U, Cohen-Kaplan V, Dowek I, Sanderson RD, Ilan N, and Vlodavsky I 2010). Proteoglycans in health and disease: new concepts for heparanase functionin tumor progression and metastasis. FEBS J 277, 3890-3903.
3. Levy-Adam F, Ilan N, and Vlodavsky I (2010). Tumorigenic and adhesive propertiesof heparanase. Semin Cancer Biol 20, 153-160.
4. Ilan N, Elkin M, and Vlodavsky I (2006). Regulation, function and clinical significanceof heparanase in cancer metastasis and angiogenesis. Int J Biochem CellBiol 38, 2018-2039.
5. Parish CR, Freeman C, and Hulett MD (2001). Heparanase: a key enzyme involvedin cell invasion. Biochim Biophys Acta 1471, M99-M108.
6. Yang Y, Macleod V, Bendre M, Huang Y, Theus AM, Miao HQ, Kussie P, Yaccoby S, Epstein J, Suva LJ, et al. (2005). Heparanase promotes the spontaneousmetastasis of myeloma cells to bone. Blood 105, 1303-1309.
7. Sanderson RD, Yang Y, Suva LJ, and Kelly T (2004). Heparan sulfate proteoglycansand heparanase-partners in osteolytic tumor growth and metastasis.Matrix Biol 23, 341-352.
8. Edovitsky E, Elkin M, Zcharia E, Peretz T, and Vlodavsky I (2004). Heparanasegene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl CancerInst 96, 1219-1230.
9. Yang Y, MacLeod V, Dai Y, Khotskaya-Sample Y, Shriver Z, Venkataraman G, Sasisekharan R, Naggi A, Torri G, Casu B, et al. (2007). The syndecan-1 heparansulfate proteoglycan is a viable target for myeloma therapy. Blood 110,2041-2048.
10. Hostettler N, Naggi A, Torri G, Casu B, Vlodavsky I, and Borsig L (2007). Pselectin-and heparanase-dependent antimetastatic activity of non-anticoagulantheparins. FASEB J 21, 3562-3572.
11. Lerner I, Baraz L, Pikarsky E, Meirovitz A, Edovitsky E, Peretz T, Vlodavsky I, and Elkin M (2008). Function of heparanase in prostate tumorigenesis: potentialfor therapy. Clin Cancer Res 14, 668-676.
12. Ferro V, Hammond E, and Fairweather JK (2004). The development of inhibitorsof heparanase, a key enzyme involved in tumour metastasis, angiogenesisand inflammation. Mini Rev Med Chem 4, 693-702.
13. Cohen-Kaplan V, Naroditsky I, Zetser A, Ilan N, Vlodavsky I, and Doweck I (2008). Heparanase induces VEGF C and facilitates tumor lymphangiogenesis. Int J Cancer 123, 2566-2573.
14. Gohji K, Hirano H, Okamoto M, Kitazawa S, Toyoshima M, Dong J, Katsuoka Y, and Nakajima M (2001). Expression of three extracellular matrix degradativeenzymes in bladder cancer. Int J Cancer 95, 295-301.
15. Doweck I, Kaplan-Cohen V, Naroditsky I, Sabo E, Ilan N, and Vlodavsky I (2006). Heparanase localization and expression by head and neck cancer: correlationwith tumor progression and patient survival. Neoplasia 8, 1055-1061.
16. Kim YJ, Borsig L, Varki NM, and Varki A (1998). P-selectin deficiency attenuatestumor growth and metastasis. Proc Natl Acad Sci USA 95, 9325-9330.
17. Borsig L, Wong R, Hynes RO, Varki NM, and Varki A (2002). Synergistic effectsof L- and P-selectin in facilitating tumor metastasis can involve non-mucinligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad SciUSA 99, 2193-2198.
18. Läubli H, Stevenson JL, Varki A, Varki NM, and Borsig L (2006). L-selectinfacilitation of metastasis involves temporal induction of fut7-dependent ligandsat sites of tumor cell arrest. Cancer Res 66, 1536-1542.
19. Läubli H and Borsig L (2010). Selectins as mediators of lung metastasis. CancerMicroenviron 3, 97-105.
20. Biancone L, Araki M, Araki K, Vassalli P, and Stamenkovic I (1996). Redirectionof tumor metastasis by expression of E-selectin in vivo. J ExpMed 183, 581-587.
21. Vlodavsky I, Ilan N, Naggi A, and Casu B (2007). Heparanase: structure, biologicalfunctions, and inhibition by heparin-derived mimetics of heparan sulfate.Curr Pharm Des 13, 2057-2073.
22. Ludwig RJ, Alban S, Bistrian R, Boehncke WH, Kaufmann R, Henschler R, andGille J (2006). The ability of different forms of heparins to suppress P-selectinfunction in vitro correlates to their inhibitory capacity on blood-borne metastasisin vivo. Thromb Haemost 95, 535-540.
23. Stevenson JL, Choi SH, and Varki A (2005). Differential metastasis inhibitionby clinically relevant levels of heparins-correlation with selectin inhibition, notantithrombotic activity. Clin Cancer Res 11, 7003-7011.
24. Bar-Ner M, Eldor A, Wasserman L, Matzner Y, Cohen IR, Fuks Z, and Vlodavsky I (1987). Inhibition of heparanase-mediated degradation of extracellular matrixheparan sulfate by non-anticoagulant heparin species. Blood 70, 551-557.
25. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, and Bevilacqua MP (1993). Heparin oligosaccharides bind L- and P-selectin and inhibit acuteinflammation. Blood 82, 3253-3258.
26. Koenig A, Norgard-Sumnicht K, Linhardt R, and Varki A (1998). Differentialinteractions of heparin and heparan sulfate glycosaminoglycans with the selectins.Implications for the use of unfractionated and low molecular weight heparinsas therapeutic agents. J Clin Invest 101, 877-889.
27. Lazo-Langner A, Goss GD, Spaans JN, and Rodger MA (2007). The effect oflow-molecular-weight heparin on cancer survival. A systematic review and metaanalysisof randomized trials. J Thromb Haemost 5, 729-737.
28. Casu B, Vlodavsky I, and Sanderson RD (2008). Non-anticoagulant heparinsand inhibition of cancer. Pathophysiol Haemost Thromb 36, 195-203.
29. Rickles FR (2006). Mechanisms of cancer-induced thrombosis in cancer. PathophysiolHaemost Thromb 35, 103-110.
30. Mousa SA (2002). Anticoagulants in thrombosis and cancer: the missing link. Semin Thromb Hemost 28, 45-52.
31. Jayson GC and Gallagher JT (1997). Heparin oligosaccharides: inhibitors of thebiological activity of bFGF on Caco-2 cells. Br J Cancer 75, 9-16.
32. Folkman J and Shing Y (1992). Control of angiogenesis by heparin and othersulfated polysaccharides. Adv Exp Med Biol 313, 355-364.
33. Vlodavsky I, Mohsen M, Lider O, Svahn CM, Ekre HP, Vigoda M, Ishai-Michaeli R, and Peretz T (1994). Inhibition of tumor metastasis by heparanaseinhibiting species of heparin. Invasion Metastasis 14, 290-302.
34. L, Wong R, Feramisco J, Nadeau DR, Varki NM, and Varki A (2001).Heparinand cancer revisited: mechanistic connections involving platelets, P-selectin,carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 98, 3352-3357.
35. Stevenson JL, Varki A, and Borsig L (2007). Heparin attenuates metastasismainly due to inhibition of P- and L-selectin, but non-anticoagulant heparinscan have additional effects. Thromb Res 120(suppl 2), S107-S111.
36. Johnstone KD, Karoli T, Liu L, Dredge K, Copeman E, Li CP, Davis K, Hammond E, Bytheway I, Kostewicz E, et al. (2010). Synthesis and biologicalevaluation of polysulfated oligosaccharide glycosides as inhibitors of angiogenesisand tumor growth. J Med Chem 53, 1686-1699.
37. Alberti A, DellaBona MA, Macciantelli D, Pelizzoni F, Sello G, Torri G, andVismara E (1996). Reactivity of glucosyl radical in the presence of phenols.Tetrahedron 52, 10241-10248.
38. Guerrini M, Mussini P, Rondinini S, Torri G, and Vismara E (1998). Electrochemicalreduction of halogenosugars on silver: a new approach to C-disaccharide-likemimics. Chem Commun 15, 1575-1576.
39. Guerrini M, Guglieri S, Santarsiero R, and Vismara E (2005). Synthesis andcharacterisation of hexa- and tetrasaccharide mimics from acetobromomaltotrioseand acetobromomaltose, and of C-disaccharide mimics from acetobromoglucose,obtained by electrochemical reduction on silver. Tetrahedron Asymmetry16, 243-253.
40. Vlodavsky I, Fuks Z, Bar-Ner M, Ariav Y, and Schirrmacher V (1983). Lymphomacell-mediated degradation of sulfated proteoglycans in the subendothelial extracellularmatrix: relationship to tumor cell metastasis. Cancer Res 43, 2704-2711.
41. Vlodavsky I (2001). Preparation of extracellular matrices produced by culturedcorneal endothelial and PF-HR9 endodermal cells. Curr Protoc Cell Biol Chapter10, Unit 10.14.
42. Nardella C, Lahm A, Pallaoro M, Brunetti M, Vannini A, and Steinkuhler C(2004). Mechanism of activation of human heparanase investigated by proteinengineering. Biochemistry 43, 1862-1873.
43. Elkin M and Vlodavsky I (2001). Tail vein assay of cancer metastasis. Curr ProtocCell Biol Chapter 19, Unit 19.12.
44. Ludwig RJ, Boehme B, Podda M, Henschler R, Jager E, Tandi C, Boehncke WH, Zollner TM, Kaufmann R, and Gille J (2004). Endothelial P-selectin asa target of heparin action in experimental melanoma lung metastasis. Cancer Res 64, 2743-2750.
45. Kragh M, Binderup L, Vig Hjarnaa PJ, Bramm E, Johansen KB, and FrimundtPetersen C (2005). Non-anti-coagulant heparin inhibits metastasis but not primarytumor growth. Oncol Rep 14, 99-104.
46. Imberty A and Perez S (2000). Structure, conformation, and dynamics of bioactiveoligosaccharides: theoretical approaches and experimental validations. ChemRev 100, 4567-4588.
47. Parish CR, Freeman C, Brown KJ, Francis DJ, and Cowden WB (1999). Identificationof sulfated oligosaccharide-based inhibitors of tumor growth and metastasisusing novel in vitro assays for angiogenesis and heparanase activity. Cancer Res59, 3433-3441.
48. Wong CH, MorisVara F, Hung SC, Marron TG, Lin CC, Gong KW, andWeitzSchmidt G (1997). Small molecules as structural and functional mimicsof sialyl Lewis X tetrasaccharide in selectin inhibition: a remarkable enhancementof inhibition by additional negative charge and/or hydrophobic group.J Am Chem Soc 119, 8152-8158.
49. Dredge K, Hammond E, Davis K, Li CP, Liu L, Johnstone K, Handley P, Wimmer N, Gonda TJ, Gautam A, et al. (2010). The PG500 series: novel heparansulfate mimetics as potent angiogenesis and heparanase inhibitors for cancertherapy. Invest New Drugs 28, 276-283.
50. Bedard PW and Kaila N (2010). Selectin inhibitors: a patent review. ExpertOpin Ther Patents 20, 781-793.
51. Gong HG and Gagne MR (2008). Diastereoselective Ni-catalyzed Negishicross-coupling approach to saturated, fully oxygenated C-alkyl and C-aryl glycosides.J Am Chem Soc 130, 12177-12183.
52. Qasba PK (2000). Involvement of sugars in protein-protein interactions. CarbohydratePolymers 41, 293-309.
53. Borsig L (2007). Antimetastatic activities of modified heparins: selectin inhibitionby heparin attenuates metastasis. Semin Thromb Hemost 33, 540-546.
54. Ley K (2003). The role of selectins in inflammation and disease. Trends MolMed 9, 263-268.
55. Laubli H and Borsig L (2010). Selectins promote tumor metastasis. Semin CancerBiol 20, 169-177.
56. Läubli H and Borsig L (2009). Heparins attenuate cancer metastasis: are selectinsthe link? Cancer Invest 27, 474-481.
57. Ludwig RJ, Schon MP, and Boehncke WH (2007). P-selectin: a common therapeutictarget for cardiovascular disorders, inflammation and tumour metastasis. Expert Opin Ther Targets 11, 1103-1117.
58. Calvey CR and Toledo-Pereyra LH (2007). Selectin inhibitors and their proposedrole in ischemia and reperfusion. J Invest Surg 20, 71-85.
59. Shafat I, Ben-Arush MW, Issakov J, Meller I, Naroditsky I, Tortoteto M, Cassinelli G, Lanzi C, Pisano C, Ilan N, et al. (in press). Preclinical and clinicalsignificance of heparanase in Ewing's sarcoma. J Cell Mol Med, DOI: 10.1111/j.1582-4934.2010.01190.x.
60. Casu B, Naggi A, and Torri G (2010). Heparin-derived heparan sulfate mimicsto modulate heparan sulfate-protein interaction in inflammation and cancer. Matrix Biol 29, 442-452.
61. Borsig L (2010). Antimetastatic activities of heparins and modified heparins.Experimental evidence. Thromb Res 125(suppl 2), S66-S71.
62. Kragh M and Loechel F (2005). Non-anti-coagulant heparins: a promising approachfor prevention of tumor metastasis [review]. Int J Oncol 27, 1159-1167.
63. McEver RP (1997). Selectin-carbohydrate interactions during inflammation andmetastasis. Glycoconj J 14, 585-591.
64. Waterman M, Ben-Izhak O, Eliakim R, Groisman G, Vlodavsky I, and Ilan N(2007). Heparanase upregulation by colonic epithelium in inflammatory boweldisease. Mod Pathol 20, 8-14.
65. Li RW, Freeman C, Yu D, Hindmarsh EJ, Tymms KE, Parish CR, and Smith PN (2008). Dramatic regulation of heparanase activity and angiogenesis geneexpression in synovium from patients with rheumatoid arthritis. Arthritis Rheum58, 1590-1600.
66. van den Hoven MJ, Rops AL, Vlodavsky I, Levidiotis V, Berden JH, and vander Vlag J (2007). Heparanase in glomerular diseases. Kidney Int 72, 543-548.